Articles related to Radiation Oncology

A Veterans Health Administration analysis of 4,890 men with metastatic hormone-sensitive prostate cancer found that achieving a PSA level below 0.2 ng/mL within 9 months was associated with improved survival. The retrospective findings support a threshold previously identified in clinical trials.

U.S. News & World Report released its 2026-27 cancer hospital rankings, with the top five cancer centers unchanged from the previous year. The rankings also introduced a new regional cancer hospital category that expands recognition beyond the national top 50.

A phase 3 trial in extensive-stage small cell lung cancer found that adding concurrent thoracic radiotherapy to chemoimmunotherapy did not improve survival outcomes and was associated with higher toxicity. Investigators reported more adverse events and treatment-related deaths, raising safety concerns about this combination strategy.

An engineered probiotic strain delivering a modified IL-2 therapy directly within pancreatic tumors slowed tumor growth and enhanced immune activity in preclinical models. Combination studies with chemotherapy, radiotherapy, and immunotherapy showed additional activity, though human data are not yet available.

A repeat PSMA PET/CT scan detected recurrent disease in more than half of prostate cancer patients whose initial scan was negative. Findings altered management in nearly half of patients, particularly those with oligometastatic recurrence.

A high-sensitivity KRAS-targeted blood test detects residual pancreatic cancer missed by standard assays, suggesting current monitoring approaches may underestimate recurrence risk despite treatment.